C. Guillemet

发表

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.

B. Weber, R. Largillier, E. Pujade-Lauraine, 2009, Gynecologic oncology.

Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

J. Picquenot, F. Clatot, A. Dujon, 2015, International journal of cancer.

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.

C. Haie-meder, F. Bertucci, B. Weber, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO).

J. Blay, S. Salas, I. Ray-Coquard, 2018, The oncologist.

Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome.

J. Blay, F. Bertucci, B. Bui, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer.

F. Clatot, O. Rigal, M. Bubenheim, 2020, European journal of cancer.

Value of CA 15-3 determination in the initial management of breast cancer patients.

D. Georgescu, C. Veyret, C. Guillemet, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress

L. Vanlemmens, V. Christophe, A. Congard, 2022, Psycho-oncology.

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.

F. Bertucci, A. Italiano, C. Balleyguier, 2022, The Lancet. Oncology.

Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group.

N. Girard, J. Blay, F. Collin, 2014, European journal of cancer.

Le carcinosarcome ovarien

O. Pradier, J. Malhaire, C. Guillemet, 2007 .

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

J. Blay, K. Kitikidou, A. Le Cesne, 2020, BMC Cancer.

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

F. Clatot, F. Di Fioré, A. Perdrix, 2018, Breast Cancer Research.

Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.

R. Rouzier, P. Colombo, I. Ray-Coquard, 2022, Gynecologic oncology.

Optimal treatment with systemic chemotherapy, complete surgical excision and hyperthermic intraperitoneal chemotherapy for a desmoplastic small round cell tumor in an adult male patient.

M. Scotté, P. Michel, F. Di Fioré, 2010, Gastroenterologie clinique et biologique.

Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database

R. Rouzier, I. Ray-Coquard, A. Floquet, 2022, Cancers.

Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.

F. Bertucci, A. Le Cesne, I. Ray-Coquard, 2015, European journal of cancer.

A large retrospective analysis of trabectedin in 885 patients with advanced soft tissue sarcoma.

J. Blay, F. Bertucci, B. Bui, 2013 .

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

J. Blay, B. Bui, A. Le Cesne, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).

F. Bertucci, A. Italiano, I. Ray-Coquard, 2019, European journal of cancer.

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.

J. Blay, F. Bertucci, S. Salas, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

F. Clatot, M. Bubenheim, F. Di Fioré, 2020, Breast Cancer Research.

The self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partners

L. Vanlemmens, P. Antoine, V. Christophe, 2018, Journal of psychosocial oncology.

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.

J. Blay, F. Bertucci, S. Salas, 2016, The Lancet. Oncology.

Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis

S. Bonvalot, O. Mir, A. Italiano, 2022, ESMO open.

Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France.

J. Blay, F. Bertucci, P. Terrier, 2016, European journal of cancer.

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.

J. Blay, B. Bui, A. Cesne, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

CxCR4 Membrane Expression in Node‐Negative Breast Cancer

J. Picquenot, E. Blot, C. Veyret, 2008, The breast journal.

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

F. Bertucci, M. Toulmonde, A. Le Cesne, 2015, The Lancet. Oncology.

Ewing‐like sarcomas with BCOR‐CCNB3 fusion transcript: A clinical, radiological and pathological retrospective study from the Société Française des Cancers de L'Enfant

O. Delattre, J. Coindre, A. Italiano, 2014, Pediatric blood & cancer.

Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC

J. Blay, F. Bertucci, S. Pannier, 2023, BMC Cancer.

LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS.

B. Weber, A. Floquet, F. Selle, 2013 .

Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.

R. Rouzier, P. Colombo, I. Ray-Coquard, 2021, Gynecologic oncology.

[Diagnosis and treatment of soft-tissue tumors].

B. Dubray, M. Debled, P. Vera, 2006, Revue de chirurgie orthopedique et reparatrice de l'appareil moteur.

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

F. Bertucci, M. Toulmonde, A. Le Cesne, 2021, ESMO open.

LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study

F. Bertucci, A. Italiano, C. Balleyguier, 2021, Annals of Oncology.

Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis.

J. Blay, S. Salas, S. Bonvalot, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.

A. Italiano, S. Piperno-Neumann, N. Penel, 2015, European journal of cancer.

Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy

F. Clatot, E. Blot, M. Ouvrier, 2009, Journal of Neuro-Oncology.

Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma

J. Blay, J. Coindre, S. Mathoulin-Pélissier, 2009, Investigational New Drugs.

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)

J. Blay, A. Le Cesne, I. Ray-Coquard, 2017, Clinical Sarcoma Research.

Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).

C. Genestie, D. Berton, I. Ray-Coquard, 2020, Gynecologic oncology.

Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.

I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, 2019, Journal of adolescent and young adult oncology.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor

F. Jardin, J. Picquenot, F. Clatot, 2016, Oncotarget.

812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial

P. Sevelda, I. Ray-Coquard, G. Scambia, 2020 .

Prospective web-based collection of sarcoma cases diagnosed and treated in France: Experience of the NetSarc network of the French Sarcoma Tumor Boards.

J. Blay, F. Bertucci, A. Cesne, 2012 .

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.

I. Treilleux, E. Kalbacher, A. Floquet, 2020, Gynecologic oncology.

Pain in desmoid‐type fibromatosis: Prevalence, determinants and prognosis value

J. Blay, F. Bertucci, S. Bonvalot, 2023, International journal of cancer.

Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses.

L. Vanlemmens, P. Antoine, V. Christophe, 2017, Future oncology.

Malignant Transformation of Mastocytoma Developed on Skin Mastocytosis Into Cutaneous Mast Cell Sarcoma

P. Courville, F. Blanchard, N. Cordel, 2012, The American journal of surgical pathology.

Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: Analysis of PAOLA-1/ENGOT-ov25 phase III trial.

K. Yonemori, I. Vergote, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

F. Clatot, F. Di Fioré, A. Perdrix, 2018, Breast Cancer Research.

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients.

C. Haie-meder, B. Weber, I. Ray-Coquard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)

J. Blay, F. Bertucci, S. Salas, 2016 .

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma

J. Blay, F. Bertucci, A. Italiano, 2020, Cancers.

EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment

R. Rouzier, T. Petit, I. Ray-Coquard, 2019, International Journal of Gynecological Cancer.

Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.

J. Blay, F. Bertucci, S. Salas, 2018 .

Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.

F. Bertucci, A. Le Cesne, I. Ray-Coquard, 2015, European journal of cancer.

C. Haie-meder, F. Bertucci, I. Ray-Coquard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[Carcinosarcoma of the ovary].

O. Pradier, J. Malhaire, C. Guillemet, 2007, Journal de gynecologie, obstetrique et biologie de la reproduction.

Effect of high-dose chemotherapy with autologous stem cell rescue (HDC-aSCR) on outcome in ovarian small-cell carcinoma, hypercalcemic type (SCCOHT): Prospective series from the French Rare Gynecologic Malignant Tumors Network (TMRG).

C. Genestie, D. Berton, I. Ray-Coquard, 2020 .

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

F. Bertucci, M. Toulmonde, A. Le Cesne, 2015, The Lancet. Oncology.